within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A07E_IntestinalAntiinflammatoryAgents.A07EA07_Beclometasone;

model Beclometasone
  extends Pharmacolibrary.Drugs.ATC.A.A07EA07;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A07EA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Beclometasone is a synthetic corticosteroid with potent anti-inflammatory properties, used primarily in the management of asthma and allergic rhinitis. The A07EA07 designation refers to its formulation for intestinal local use (as beclometasone dipropionate) in the treatment of inflammatory bowel diseases such as ulcerative colitis. It is an approved drug used in various formulations including inhaled, nasal, and rectal.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for beclometasone dipropionate in adult patients after oral administration for local (intestinal) treatment. No direct human pharmacokinetic studies for A07EA07 have been found; values are based on extrapolations from reported data for other routes and the known poor systemic bioavailability.</p><h4>References</h4><ol><li><p>Doan, PL, &amp; Chao, NJ (2009). The role of oral beclometasone dipropionate in the treatment of gastrointestinal Graft-versus-Host Disease. <i>Drugs</i> 69(10) 1339–1350. DOI:<a href=\"https://doi.org/10.2165/00003495-200969100-00004\">10.2165/00003495-200969100-00004</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19583452/\">https://pubmed.ncbi.nlm.nih.gov/19583452</a></p></li><li><p>Naclerio, RM (1998). Optimizing treatment options. <i>Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology</i> 28 Suppl 6 54–59. DOI:<a href=\"https://doi.org/10.1046/j.1365-2222.1998.0280s6054.x\">10.1046/j.1365-2222.1998.0280s6054.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/9988437/\">https://pubmed.ncbi.nlm.nih.gov/9988437</a></p></li><li><p>Daley-Yates, PT, et al., &amp; Dallow, N (2001). Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man. <i>British journal of clinical pharmacology</i> 51(5) 400–409. DOI:<a href=\"https://doi.org/10.1046/j.0306-5251.2001.01374.x\">10.1046/j.0306-5251.2001.01374.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11421996/\">https://pubmed.ncbi.nlm.nih.gov/11421996</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Beclometasone;
